欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

午间休市 01-02 12:05:00

7.490

+0.090

+1.22%

最高7.820	最低7.490	成交量14.15万
今开7.780	昨收7.400	日振幅4.46%
总市值61.04亿	流通市值61.04亿	总股本8.15亿
成交额107.21万	换手率0.02%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.49,"timestamp":1767326700004,"preClose":7.4,"halted":0,"volume":141500,"delay":0,"floatShares":815000000,"shares":815000000,"eps":-0.4383337806723016,"marketStatus":"午间休市","change":0.09,"latestTime":"01-02 12:05:00","open":7.78,"high":7.82,"low":7.49,"amount":1072060,"amplitude":0.044595,"askPrice":7.49,"askSize":9500,"bidPrice":7.46,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.37188050071281104,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767330000000},"marketStatusCode":3,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":7.4,"openAndCloseTimeList":[[1767317400000,1767326400000],[1767330000000,1767340800000]],"volumeRatio":0.228619,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2600058740","title":"港股异动 | 晶泰控股(02228)早盘涨超8% 公司业务已实现从AI制药到AI4S平台延伸","url":"https://stock-news.laohu8.com/highlight/detail?id=2600058740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600058740?lang=zh_cn&edition=full","pubTime":"2026-01-02 11:31","pubTimestamp":1767324690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，晶泰控股早盘涨超8%，截至发稿，涨6.98%，报10.12港元，成交额1.29亿港元。申万宏源发布研报称，晶泰控股依托“物理计算+AI+机器人”核心技术，构建了从算法、引擎到自动化实验室的早期药物研发完整闭环。公司业务已实现从AI制药向更广阔的“AI4S”平台延伸，其底层技术不仅能加速创新药研发各环节，也具备向新材料等领域迁移的潜力，展现出强大的技术广度与平台化价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","02228","BK1141","BK1617","BK1191"],"gpt_icon":0},{"id":"2595725207","title":"中金快讯 | 中金公司保荐AI制药龙头“英硅智能”完成港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725207","media":"中金公司CICC","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595725207?lang=zh_cn&edition=full","pubTime":"2025-12-31 19:02","pubTimestamp":1767178969,"startTime":"0","endTime":"0","summary":"12月30日，InSilico Medicine Cayman TopCo正式在香港联交所主板挂牌上市。本次交易是迄今为止规模最大的AI制药企业港股IPO项目，亦是2025年以来规模最大的Biotech企业港股IPO项目。在全球资本市场环境不断变化的背景下，中金公司长期陪伴英硅智能，自2022年持续为公司提供跨市场的全方位服务。英硅智能是一家业务遍布全球的AI驱动药物发现及开发公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231215011a48eda2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231215011a48eda2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","LU0359201885.HKD","BK1516","BK1147","BK1574","LU1023057109.AUD","BK1191","03908","BK1501","01477","LU0359201612.USD","LU0359202008.SGD","BK1564","SG9999002828.SGD"],"gpt_icon":1},{"id":"2595747786","title":"AI 制药合作潮下，药物研发已进入“深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2595747786","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595747786?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:21","pubTimestamp":1767151265,"startTime":"0","endTime":"0","summary":"值得注意的是，基于此，AI+制药领域的合作开始不断增多，研发领域也开始从小分子药物向多肽药物和双特异性抗体等拓展。如12月11日，腾盛博药宣布与OpenBench达成合作，将利用OpenBench的结构驱动人工智能平台，加速腾盛博药在创新药物发现领域的研发进程，并推动其专有技术平台的应用。12月9日，甘李药业宣布与晶泰控股达成代谢疾病领域AI多肽创新药的研发合作及AI技术平台使用授权协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112307a6e3b8d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231112307a6e3b8d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","01477","BK1191","BK1574","02137"],"gpt_icon":1},{"id":"2595797761","title":"6新股年末组团敲锣！缩短研发周期 港股市场热捧AI制药｜港股直通车","url":"https://stock-news.laohu8.com/highlight/detail?id=2595797761","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595797761?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:05","pubTimestamp":1767099948,"startTime":"0","endTime":"0","summary":"12月30日，港交所迎来六家公司集体挂牌上市，包括护肤品牌林清轩（HK02657）、建筑服务商美联股份（HK02671）、数据基础设施企业迅策（HK03317）、人工智能药物研发公司英硅智能（HK03696）、机器人企业卧安机器人（HK06600）以及数字孪生科技公司五一视界（HK06651）。其中，英硅智能开盘报35港元，较发行价大幅上涨45%，成为当日亮点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605959470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605959470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2595276324","title":"高瓴红杉投出一个AI制药IPO，市值195亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2595276324","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595276324?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:56","pubTimestamp":1767066974,"startTime":"0","endTime":"0","summary":"来源：直通IPO，文/韩文静12月30日，英硅智能登陆港股主板，本次发行定价24.05港元/股，计划发行9469.05万股，预计募资约22.77亿港元。今年5月，英硅智能继续向港交所提交上市申请；11月初，英硅智能再度更新港股招股书。依托这套体系，英硅智能建立了30余条丰富的自研管线组合，10个项目已获不同监管机构颁发的开展临床试验批件，其中多项资产已授权给国际制药企业，最大的3个项目合约总价值超过21亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230115621a6df902d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"3800b70a39b2b6017b3a0f21f56e5031","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230115621a6df902d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2595763364","title":"英硅智能在港交所主板挂牌上市 成为港股“AI制药第一股”","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763364","media":"e公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763364?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:14","pubTimestamp":1767064440,"startTime":"0","endTime":"0","summary":"12月30日，英硅智能正式在港交所主板挂牌上市，成为港股“AI制药第一股”。目前，英硅智能AI制药项目落地于无锡市宜兴陶都科技新城。未来，英硅智能将借助在宜兴建立的创新业务总部研发平台，在AI辅助大分子药物研发领域，利用其独有的生成式人工智能技术，正式进军大分子药物的研发赛道。在本次提交港股IPO申请前，英硅智能已开展了5轮主要融资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230111636a4886c8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230111636a4886c8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1574"],"gpt_icon":1},{"id":"2595784352","title":"白云山最新公告：分公司白云山制药总厂注射用头孢呋辛钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784352","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784352?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:49","pubTimestamp":1767005395,"startTime":"0","endTime":"0","summary":"白云山公告称，公司分公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》，注射用头孢呋辛钠及注射用头孢呋辛钠通过仿制药质量和疗效一致性评价，并同意相关变更。头孢呋辛钠为第二代头孢菌素，临床广泛用于治疗呼吸道感染、泌尿系统感染及外科感染。该药品被列入国家基本药物目录和国家医保乙类品种。白云山制药总厂已投入研发费用约1,042.10万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900026894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK1606","BK0028","BK1515","BK0196","BK0012","00874","BK0097","BK0183","BK0175","BK0188","BK0070","BK1191","BK1197","BK1521","01477","BK1574","600332","BK0239"],"gpt_icon":0},{"id":"2595813687","title":"歌礼制药-B(01672)12月29日斥资248.29万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595813687","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595813687?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:22","pubTimestamp":1767003744,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月29日，该公司斥资248.29万港元回购20万股股份，每股回购价格为12.17-12.66港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","01477","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"2595766925","title":"每日卖空追踪 | 歌礼制药-B 12月29日卖空量成交14万股，卖空比例为6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595766925","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595766925?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997022,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月29日，跌3.57%，卖空量成交14万股，较上一交易日减少16.17%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163253a6dc4814&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163253a6dc4814&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","01477","01672","BK1161","BK1191"],"gpt_icon":0},{"id":"2595203585","title":"东方证券：首予歌礼制药-B(01672)“买入”评级 目标价18.38港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595203585","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595203585?lang=zh_cn&edition=full","pubTime":"2025-12-29 10:27","pubTimestamp":1766975272,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，预测歌礼制药-B2025-2027年每股收益分别为-0.32/-0.35/-0.38元，对公司自由现金流进行绝对估值，预测公司合理市值为183.66亿港元，对应目标价为18.38港元，首次给予“买入”评级。当前减重药物主要为GLP-1药物，临床中使用率低、依从性差、停药后体重反弹明显和瘦体重流失问题较为突出。该行认为，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01672","03958","01477","600958"],"gpt_icon":0},{"id":"2594299145","title":"新股消息 | 麓鹏制药拟港股上市 中国证监会要求补充说明搭建离岸架构及返程并购的合规性等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2594299145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594299145?lang=zh_cn&edition=full","pubTime":"2025-12-26 20:56","pubTimestamp":1766753800,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示19家企业补充材料要求，其中，要求麓鹏制药补充说明搭建离岸架构及返程并购的合规性等事项。该公司的核心产品LP-168是全球首个且唯一的“共价兼非共价”双重BTK抑制剂，在肿瘤学及自身免疫性疾病领域均具备同类最佳潜力。LP-168在多项肿瘤学及自身免疫性疾病适应症中展现显著临床效益，并呈现卓越的安全性，其治疗相关不良事件发生率低于先前BTK抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2594325913","title":"石药创新制药股份有限公司股东会通过多项重要议案，包括变更会计师事务所及补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2594325913","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594325913?lang=zh_cn&edition=full","pubTime":"2025-12-25 18:00","pubTimestamp":1766656800,"startTime":"0","endTime":"0","summary":"中访网数据石药创新制药股份有限公司于2025年12月25日召开了2025年第三次临时股东会。核心决策包括：同意将部分已结项的募集资金投资项目节余资金永久补充流动资金并注销相关专户；批准了公司2026年度与关联方的日常交易预计额度；决议变更公司年度审计会计师事务所；以及授权公司及子公司向银行申请2026年度综合授信额度。其中，关联交易议案因涉及关联方，相关股东已依法回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225180131a6ce2687&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225180131a6ce2687&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0314109678.HKD","LU0072913022.USD","LU1152091168.USD","IE0008369823.USD","LU1328277881.USD","LU1807302812.USD","IE00B5MMRT66.SGD","01477","LU1152091754.HKD","LU2039709279.SGD","01093","IE00BZ08YT58.USD","BK1191","IE00BZ08YS42.EUR","LU0315179316.USD","LU0326950275.SGD","LU1226287529.USD","LU1226288170.HKD","BK1515","HK0000165453.HKD","LU0140636845.USD","BK1574","BK1521","LU0501845795.SGD","LU1960683339.HKD","LU1226288253.USD","LU1008478684.HKD","SG9999004220.SGD","LU1993786604.SGD","IE0008368742.USD","LU0880133367.SGD","LU1226287792.SGD","IE00B543WZ88.USD","LU1226287875.USD","LU1813983027.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0067412154.USD"],"gpt_icon":0},{"id":"2593763144","title":"资本涌入、合作爆发，AI制药迈入加速发展期｜记“医”2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2593763144","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593763144?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:04","pubTimestamp":1766570656,"startTime":"0","endTime":"0","summary":"在技术突破的推动下，全球AI制药行业正呈现多点开花的发展态势。摩熵投融资数据显示，今年以来，全球AI制药相关投融资事件近80起。随着技术与资本的双重加持，AI制药有望加速创新药物问世，为全球患者带来新的治疗希望。目前，全球十大制药巨头均已布局AI。另外，据国金证券统计，截至2025年11月21日，今年全球AI制药BD交易已达12项。万联证券指出，企业合作共担风险有利于推动AI制药从“概念”走向“现金流”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224180826a6c9e1e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224180826a6c9e1e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03696","BK1191","BK1574","01093","01477"],"gpt_icon":1},{"id":"2593403575","title":"每日卖空追踪 | 歌礼制药-B 12月24日卖空量成交16.7万股，卖空比例为16.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593403575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593403575?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:30","pubTimestamp":1766565021,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月24日，涨1.69%，卖空量成交16.7万股，较上一交易日减少69.47%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163320a4727ed2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163320a4727ed2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","01672","BK1574","01477","BK1161"],"gpt_icon":0},{"id":"2593413090","title":"复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413090","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413090?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:08","pubTimestamp":1766498900,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，复星医药在互动平台回答投资者提问时表示，公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块，其中药品、器械及诊断产品的主要市场包括中国、美国、欧洲及新兴市场在内的多个国家和地区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599787764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK1593","600196","XBI","BK1583","BK4581","BK0188","09996","01477","BK0028","BK0012","BK0096","BK0239","BK1100","BK0187","BK1515","BK4588","02196","BK0060","BK0183","BK0196","09997","BK1574","159883","BK1222","XLV","159760","BK1191","BK0175","LABU"],"gpt_icon":0},{"id":"2593432493","title":"石药创新制药股份有限公司控股子公司达雷妥尤单抗注射液获临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2593432493","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593432493?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:55","pubTimestamp":1766480123,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。公司表示将于近期启动临床试验。此次获得临床试验批准是该药物研发进程中的关键一步，但后续仍需完成临床试验并经国家药监局批准后方可上市销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251223/31884943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","01477","HK0000165453.HKD","LU1951186391.HKD","LU0314109678.HKD","LU0326950275.SGD","BK1191","BK1515","LU1993786604.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1328277881.USD","IE0008368742.USD","LU0072913022.USD","IE00B543WZ88.USD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287529.USD","01093","LU1152091168.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU0067412154.USD","LU0501845795.SGD","LU0315179316.USD","LU1226287875.USD","LU1226287792.SGD","LU1807302812.USD","BK1521","LU1813983027.USD","SG9999004220.SGD","LU0880133367.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","LU1008478684.HKD","LU1226288170.HKD","LU1960683339.HKD","LU2039709279.SGD"],"gpt_icon":0},{"id":"1130488131","title":"港股创新药概念股盘中拉升！石药集团涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130488131","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130488131?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:04","pubTimestamp":1766455472,"startTime":"0","endTime":"0","summary":"12月23日，港股创新药概念股盘中拉升，$石药集团(01093)$涨超5%，$恒瑞医药(01276)$、$三生制药(01530)$涨近3%，$先声药业(02096)$、$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26e483f2c2080ad5ab71efdf30a08f1a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","02162","01276","01530","01093","01672","06978","01477"],"gpt_icon":0},{"id":"2593414568","title":"齐鲁制药旗下申可安在阿里健康首发为“剂末现象”帕金森病患者提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2593414568","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593414568?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:52","pubTimestamp":1766454720,"startTime":"0","endTime":"0","summary":"12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药方案，提升患者依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1615","BK1191","BK1591","BK1610","BK1189","BK1501","BK1515","00241","BK1589","01477","BK1247","BK1571","BK1584","BK1574","BK1617","BK1142","BK1502"],"gpt_icon":0},{"id":"2593485449","title":"歌礼制药-B(01672)12月22日斥资249.37万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485449?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:54","pubTimestamp":1766397251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月22日，该公司斥资249.37万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","BK1515","01477","BK1161","01672"],"gpt_icon":0},{"id":"2593486488","title":"每日卖空追踪 | 歌礼制药-B 12月22日卖空量成交34.1万股，卖空比例为11.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593486488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593486488?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392224,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月22日，跌3.77%，卖空量成交34.1万股，较上一交易日减少45.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163432a6c09b69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163432a6c09b69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1161","BK1515","BK1574","01672"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0561},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.1365},{"period":"6month","weight":-0.1859},{"period":"1year","weight":0.6444},{"period":"ytd","weight":0.6444}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家控股公司，主要从事眼科治疗药物的研发和商业化。该公司主要产品包括OT-401 (YUTIQ)、OT-1001 (ZERVIATE)、OT-502 (DEXYCU)、OT-301 (NCX 470)、OT-101和OT-202等。该公司业务主要在国内市场开展。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.116968},{"month":2,"riseRate":0.4,"avgChangeRate":-0.049128},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}